Moderna shares climb nearly 100% as mRNA vaccine with Merck succeeds in large trial for skin cancer | Stock Market News

The study is ongoing, but interim results found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of keeping cancers from spreading to other parts of the body



Source link